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COMMENTARY
Continued importance in translation 
from research to health policy in China
Jun Zhang1,2, Fan Jiang3 and Xiaoming Shen4*
Abstract 
Precision Medicine may be considered as another strategic effort of “from-bench-to-beside” translation. In order to 
have a maximal impact on population health, the translation must go further. A new translational medicine paradigm 
is proposed to improve the clarity of conceptual pathways and facilitate translation from research to health policy. The 
latter is particularly important in low- and middle-income countries where the need to improve population health is 
immediate and immense.
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The Precision Medicine Initiative proposed by the 
president of the United States (U.S.) last year has swept 
through the research landscape in China. It is considered 
by some as a new direction of future research and a new 
model for health care delivery [1]. The National Health 
and Family Planning Commission of China reportedly 
plans to spend 60 billion Ren Min Bi (RMB) (US$9.2 bil-
lion) in Precision Medicine in the next 15 years [2].
At the core of the Precision Medicine Initiative lies the 
proposal to use (1) large databases such as the human 
genome sequence; (2) individual characterizing infor-
mation from modern technologies such as proteomics, 
metabolomics, genomics, and diverse cellular assays; (3) 
computational tools for analyzing big data; and (4) mobile 
health technology, to prevent and treat diseases by tak-
ing variability of individual patients into account [3]. The 
concept is noble but to implement this strategy requires 
seas of knowledge. Precision testing alone is insufficient; 
making clinical sense of the testing results, counseling 
patients, judging clinical actionability and providing 
clinical guidance to patient care are essential. To this end, 
the Initiative plans to launch a large prospective cohort 
study of over 1 million Americans to obtain necessary 
information and translate it into clinical practice. Recent 
requests for proposals from the Ministry of Science and 
Technology of China followed suit. In addition to a mil-
lion-people cohort, China goes further to establish more 
than a dozen of disease-specific cohorts with a focus on 
treatment and prognosis research. If translational medi-
cine emphasizes the process from research to practice to 
policy, Precision Medicine is a method of research and 
practice. In essence, Precision Medicine is another strate-
gic effort of from-research-to-practice translation.
But the translation must go further. If the ultimate 
goal of translational medicine is to improve health of 
the population, translation from research to prevention 
and health policy remains to be of critical importance, 
especially in low- and middle-income countries [4]. 
We hereby propose a new paradigm that hopefully can 
improve the clarity of conceptual pathways and facili-
tate translation from medical research to health policy 
(Fig. 1).
There are two similar but distinct pathways in trans-
lational research. The clinical pathway has been well 
characterized in the past decade and the importance of 
translating basic science discoveries into clinical appli-
cation and from clinical practice to health care policy, 
eventually benefitting a large population has been dem-
onstrated in a number of successful examples in China 
[5]. However, the preventive medicine pathway is much 
less well conceptualized and popularized. Epidemiologic 
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or health promoters (e.g., exercise). Health promoters 
can also come from basic and/or clinical research, e.g., 
vaccines. Through rigorous testing, most often by ran-
domized field trials, effective preventive measures and 
health promoters are established. Yet, implementation 
of preventive strategies in community also requires deep 
knowledge in health care delivery and disease prevention 
systems, health economics, health education and behav-
ior modification, and even relevant regulation and law. 
T3 is a process of knowledge acquisition through social 
and behavioral studies and knowledge transfer from aca-
demic setting to community. If a preventive measure can 
be successfully implemented and demonstrate its effec-
tiveness, setting up a corresponding public health policy 
should be advocated (T4).
In the context of Precision Medicine, certain cancer 
treatments have taken the lead in the clinical pathway 
and the treatment success was improved substantially 
[6]. Yet, much research is needed particularly in treating 
common diseases, which will have much greater implica-
tions in health care policy. More importantly, and prob-
ably more difficult as well is to establish personalized 
prevention. Evidence indicates that for common and 
complex diseases such as hypertension, genetics accounts 
for a small proportion of the etiology; environment and 
behavioral factors are the main determinants of such dis-
eases. Thus, while genetic information is helpful, avail-
able literature does not seem to lend a strong support yet 
for a policy of universal gene sequencing for the purpose 
of prevention, despite that the cost of whole genome 
sequencing has dropped substantially. The interpreta-
tion of genome sequencing results is another significant 
challenge. The prevention pathway of the translational 
medicine framework remains as an important process to 
translate from research to public health policy in China 
in the near future.
In spite of some successes in our own practice in pol-
icy translation [7], an efficient and effective channel and 
applicable process to transfer knowledge from acad-
emicians to policy makers have not been established in 
China; nor is it being systematically practiced. Most phy-
sicians and scientists feel that T4 is out of their reach and, 
therefore, may not have the desire to carry out advocacy. 
Policy makers, on the other hand, often have multiple 
issues at hand that compete for their attention. Evidence 
shows that it is critical to build and maintain a good rela-
tionship and trust between researchers and policy mak-
ers [8]. Policy makers also rank direct interaction with 
researchers as the most effective way to take up science 
into policy [9]. It is beneficial for researchers to inform 
and engage policy makers in research process as early as 
possible and throughout the study period. In addition, 
policy makers need synthesized evidence that is easy to 
understand and communicate [8]. Consequently, “knowl-
edge broker” or “professional communicator” model 
was proposed to facilitate the communications between 
researchers and policy makers [10].
China offers great opportunities to apply evidence-
based policy to the field because it is undertaking tre-
mendous infrastructure and capacity building as well as 
system reforms. An individual scientific discovery may 
be translated or localized into one particular policy. Mul-
tiple scientific advances may be embedded in one com-
prehensive system reform. And a large national or city 
project may incorporate a number of health policies and 
scientific innovations.
To achieve these requires both researchers and policy-
makers to change their mindset, value and invest in trans-
lation research. Funding agencies in North America and 
Europe often explicitly require plans and tangible meas-
ures for knowledge translation and policy implications 
in grant applications in recent years. A number of cent-
ers for translation research were funded by the National 
Institutes of Health (NIH) across the U.S. Within NIH 
a Center for Translation Research and Implementation 
Fig. 1 A new translational medicine paradigm. Steps in translational 
medicine
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Science was established last year [11]. These models 
and, more importantly, their contents deserve a care-
ful assessment in China. We would further suggest that 
local governments may also consider supporting transla-
tion research centers with T4 translation as part of the 
mandate to address urgent local needs. Policy makers can 
solicit ideas from researchers to solve local problems. A 
review board may select promising candidates and com-
municate with policy makers for further consideration. 
When a sound health policy is successfully translated and 
effectively applied, the results can be especially reward-
ing in China in terms of the scale of impact and the mag-
nitude of change in a relatively short time [7].
In summary, the Precision Medicine Initiative propels 
the translational medicine movement to another height. 
For a country like China, which accounts for 20  % of 
the world’s population, the need to improve population 
health is immediate and immense. It will be imperative 
to maximize the benefits of the discoveries by Precision 
Medicine, not only for treatment but, more importantly, 
for disease prevention. When we try to advance Precision 
Medicine, the bigger picture of Translational Medicine, 
particularly the translation from research to health poli-
cies, should not be forgotten.
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